Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target.
Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target.
复制标题
DOI：
10.1053/j.ajkd.2015.09.027
复制
发表时间：
2016-03
期刊：
影响因子：
--
通讯作者：
Raj DS
中科院分区：
文献类型：
--
作者：
Ramezani A;Massy ZA;Meijers B;Evenepoel P;Vanholder R;Raj DS
肠道微生物组也被称为“第二个人类基因组”，在维持健康和疾病发病机制方面发挥着重要作用。由于慢性肾脏病（CKD）患者中的微生态失调细菌的增殖，宿主与微生物组之间的共生关系受到干扰。肠道细菌对蛋白质和氨基酸的发酵产生过量的潜在有毒化合物，如氨、胺、硫醇、酚和吲哚，但短链脂肪酸的产生减少。CKD患者的肠屏障功能受损，可使肠源性尿毒症毒素易位至体循环中，导致CKD、心血管疾病、胰岛素抵抗和蛋白质能量消耗的进展。微生物组研究领域仍处于萌芽阶段，但发展迅速。建立共生来治疗尿毒症综合征是一个新的概念，但如果被证明是有效的，将对CKD患者的管理产生重大影响。
Also known as the “second human genome,” the gut microbiome plays important roles in both the maintenance of health and the pathogenesis of disease. The symbiotic relationship between host and microbiome is disturbed due to proliferation of dysbiotic bacteria in patients with chronic kidney disease (CKD). Fermentation of protein and amino acids by gut bacteria generate excess amounts of potentially toxic compounds such as ammonia, amines, thiols, phenols, and indoles, but generation of short chain fatty acids is reduced. Impaired intestinal barrier function in CKD permits translocation of gut-derived uremic toxins into the systemic circulation, contributing to progression of CKD, cardiovascular disease, insulin resistance, and protein energy wasting. The field of microbiome research is still nascent, but evolving rapidly. Establishing symbiosis to treat uremic syndrome is a novel concept, but if proven effective will have significant impact on the management of patients with CKD.